2015 China (Chongqing) biomedical frontier technology and participatory development seminar held successfully

With the implementation of "healthy China 2020", "made in China 2025" and other national plans, as well as the continuous deepening of the reform of national medical reform, drug and medical device review and approval system, and the introduction of a series of measures, encouraging biomedical innovation, improving product quality, strengthening international cooperation, promoting the transformation of scientific and technological achievements and industrial transformation and development have gradually become the development of China's biomedical industry The mainstream direction of In order to better respond to the needs of promoting national policies and scientific research industry cooperation and innovation, the 2015 China (Chongqing) biomedical frontier technology and industrialization development seminar sponsored by China Pharmaceutical Enterprise Development Promotion Association, China pharmaceutical scientific and technological achievements transformation center, under the guidance of Chongqing pharmaceutical industry development office and sponsored by the Journals of Gaosheng pharmaceutical, Weston biology and the Third Military Medical University The meeting was held in Chongqing from December 19 to 20 The seminar invited scholars from well-known domestic research and transformation institutions, authoritative experts in industrialization and senior executives of pharmaceutical enterprises as speakers, and made reports and exchanges on the two themes of "pharmaceutical innovation and industrialization development" and "frontier technology transformation of biomedicine", aiming to actively promote the introduction technology innovation and cooperation exchange of biomedicine and promote the collaborative innovation of biomedicine in Chongqing And industrial cluster development Opening ceremony: on the morning of December 19, the seminar was officially opened in a peaceful and lively atmosphere under the gracious chairmanship of Qin Dan, host of Chongqing TV station, and sun Qinghua, deputy director of general management department of Chongqing pharmaceutical industry development office Zhang Wenzhou, former deputy director of the State Food and drug administration, President of China Pharmaceutical Press Association, Yu Shanjiang, deputy director of the Pharmaceutical Biotechnology Department of China Biotechnology Development Center, Ministry of science and technology, Yao Tongli, vice president of China Pharmaceutical Enterprise Development Association, Rui Guozhong, director of China Pharmaceutical Technology Achievement transformation center, Yang Liqiong, deputy director of Chongqing Economic and Information Technology Commission, Chongqing Medical Zhang Yilong, President of the pharmaceutical industry association, Wu Jingming, vice president of the people's Government of Hechuan District, Chongqing, Li Xiaoping, director of the medical device supervision department of Chongqing food and drug administration, and Xie Zhijie, director of the Development Department of Chongqing Medical Industry Development Office attended the opening ceremony as special guests At the beginning of the conference, Mr Zhou Yong, the founder of gaochuanghui, delivered a speech He said that with this seminar, we will gather wisdom and seek common future with the original intention of "innovation, cooperation, development and win-win" At the same time, Zhou Yong expressed sincere welcome and thanks to all the guests who came to this grand meeting Later, Yang Liqiong, deputy director of Chongqing Economic and Information Technology Commission, made a speech By reviewing the development of Chongqing pharmaceutical industry, summarizing the current situation, reflecting on the problems and looking forward to the future, deputy director Yang stressed that the integration of production, learning and research is crucial to the innovation output, technology transformation and industrial development of the biomedical industry Chongqing, as a municipality directly under the central government where the biomedical industry is booming, has given the greatest support and support to the development of Medicine on the basis of the existing good platform, and is willing to provide a better platform and system for scientific research scholars, pharmaceutical enterprises and investment experts, so as to create a Highland for the development of medicine As one of the representatives of the organizers, Yao Tongli, vice president of China Pharmaceutical Enterprise Development Association, delivered a speech on the smooth opening of this grand meeting Yao Tongli said that when the health China 2020 plan medical reform was carried out in depth, it was a good opportunity to promote the innovation and cooperation of biomedical achievements by discussing the policy environment, cutting-edge technology and other focus topics to promote the development of biomedical As a social organization of the national pharmaceutical industry, China Pharmaceutical Enterprise Development Association always aims to serve the pharmaceutical industry and promote the development of enterprises Zhang Yilong, chairman of Chongqing pharmaceutical industry association, made a speech as the representative of the conference co organizer Zhang Yilong stressed that the combination of scientific research achievements with upstream and downstream industrial chains is an important process for the achievement of value and technology transformation After the speech, Yu Shanjiang, deputy director of the Pharmaceutical Biotechnology Department of China Biotechnology Development Center of the Ministry of science and technology, made a thematic report on the relevant policy trends of the development of biomedical industry in the 13th five year plan of China Yu, deputy director of science and technology planning management reform of the background and problems are briefly described, as an opportunity and starting point to start the reform of science and technology management He gave a detailed introduction to the overall goal, overall planning and main tasks of management reform Rui Guozhong, director of China Center for transformation of pharmaceutical scientific and technological achievements, as the theme guest, gave a wonderful report on the development trend and model innovation of international cooperation in pharmaceutical innovation Because drug innovation is a complex economic activity with long cycle, high investment, high risk and strict supervision, cooperative development has become a hot spot of national cooperation in drug innovation Referring to the internationalization process of China's pharmaceutical innovation, director Rui said that with the interaction and overlap of more transformation elements, he believed that in the future, China will present a variety of strategies to advance simultaneously, and the nationalization of Chinese pharmaceutical enterprises is not far from warm Wu Jingming, vice president of Hechuan District People's Government of Chongqing, combined with his own experience, made a report on the theme of "opportunity Hechuan" based on the interpretation of the development policies of the pharmaceutical industry in Hechuan District of Chongqing Located in the intersection of Jialing River, Qujiang River and Fujiang River, Hechuan has unique geographical conditions and cultural heritage, and is a key node to drive the development of the western region In the pharmaceutical industry, Hechuan government supports the construction and development of enterprises in an all-round way by means of enterprise introduction, new drug R & D funding, basic drug catalog subsidy, etc., as well as from the handling of formalities to the integrated service of market promotion Topic discussion: pharmaceutical innovation and industrialization development Chen Ming: Research Fellow, Institute of Biochemistry and cell biology, Shanghai Institute of life sciences, Chinese Academy of Sciences, director of chemical biotechnology platform - "innovation driven new drug screening and development platform construction" In combination with the layout of "one body, two wings" of Institute of Biochemistry and cell, Chinese Academy of Sciences, researcher Chen Ming focuses on the chemical biology technology platform (cbcf) Cbcf provides services for all research groups in the aspects of originality and application type By means of high-throughput test technology, it uses siRNA / shRNA / cDNA library to screen functional genome, to explore new potential drug targets while promoting the original research, and to screen small molecule active compounds for the original new targets by using various small molecule compound libraries, so as to develop new small molecules Molecular probe or drug base Through cooperation and complementarity between scientific research institutes and industrial institutions, innovation driven new drug research and development can be realized Yang Dajian: Director of Chongqing Research Institute of traditional Chinese medicine, the research and development of traditional Chinese medicine, as the support of the old brand industry of Chongqing biomedicine, has accumulated certain experience and new in scientific research innovation and achievement transformation Yang Yuanchang put the concepts of scientific research achievements, equity of scientific research achievements and intangible assets into the topic, and emphasized that scientific and technological achievements need to be reasonably transformed to optimize resources and promote the development of enterprises through the actual cases of Chinese Medicine Research Institute Among them, the pharmaceutical factory of Chongqing Research Institute of traditional Chinese medicine will use its equity to motivate scientific and technological personnel and other contributing personnel, so as to realize the activation of intangible assets through the equity of scientific and technological achievements In addition, the Research Institute's scientific and technological achievements are first internal equity, and then through joint venture with a third party to establish Dianjiang branch, to realize joint operation and serve the big health industry President Yang emphasized that scientific research achievements, as a kind of intangible assets, only through transformation can they really have value, and equity is a good choice At the beginning of the report, Zou, director of Chongqing biopharmaceutical engineering technology research center and director of national immune biopharmaceutical Engineering Technology Research Center, pointed out that there was a great difficulty in the research and development of original new drugs, including a long cycle, high funding, the need for a composite high-tech talent team, the need for expensive high-end equipment, and a high failure rate Combined with his own scientific research experience, from the construction of experimental platform, the selection of projects, project implementation to the realization of projects, Director Zou believes that innovation lies in the core position of creation and entrepreneurship, in which the innovation of thinking and thinking is the core Director Zou encouraged his colleagues and young workers present Although there is no easy way to innovate, only by adhering to ideals and not giving up easily can we hope to move from innovation to creation Later, Ms Huang Qunying, vice president of Sinopharm Chongqing, and Li Tiantian, founder of DXY, respectively made wonderful reports on the innovation industrialization of taxol Taxus and the development and practice of mobile medical industry of Sinopharm Topic discussion: Transformation of biomedical cutting-edge technology Fu ailing: Professor, School of medicine, Southwest University, postdoctoral of Fudan University, targeting of polypeptide guided source materials into neural cells is the consensus of cancer treatment at present Aiming at the targeting of neural cancer cells, Dr Fu ailing, who is engaged in neurobiological research, has brought us good news Dr Fu's experimental group found through a large number of studies that the reason why rabies cells are invasive is from polypeptides Through further verification, the targeted biomarkers were used in vivo experiments, and it was found that the brain and spinal cord were obviously labeled, which fully proved that polypeptides could guide the biomaterials to selectively enter the nerve cells, and may also be an important basis for the future targeting of nerve cancer Shen Youfeng, technical director of CRISPR / cas9 of Gaosheng pharmaceutical, the innovation and application of CRISPR / cas9 technology gene targeting drug, using CRISPR / cas9 gene knock out technology to establish disease model and human disease treatment will be one of the important directions for future development Shen Youfeng introduced that using talen technology to knock out the p53 gene and knock out the p53 gene and overexpress the H-ras + c-myc gene at the same time, and successfully constructed a pig tumor model At present, the laboratory project team has established CRISPR / cas9 technology system to knock out GGTA1 gene, H19 gene, lepton gene, etc Shen Youfeng said that CRISPR / cas9 technology is becoming more and more mature, and its application in human disease treatment in the future will not be fruitful Li Tianquan: co founder, general manager of R & D and senior engineer of pharmaceutical intelligence network, the future era of "data perspective on the current situation and trend of China's new drug R & D" is the era of data, including medical big data Li Tianquan, the co-founder of yaozhi.com, who has been engaged in data analysis, believes that the data has been recording the development of China's pharmaceutical industry Before 2005, China's new drug applications were flying all over the world In 2006, the Qing Dynasty purged, and in 2007, chemical application 283, traditional Chinese medicine 331, and biological medicine 42 were applied This situation continued until this year's 7.22 massacre Clinical trials verified that a drug application reappeared its trough 。 In the end, Li Tianquan said that mastering the data can be described as mastering the development trend of the future pharmaceutical market If you need to, you can log in to the website of pharmaceutical intelligence http://db.yaozh.com/ for inquiry In the agenda of the conference, Pei Desheng, director of environment and health research center of Chongqing Institute of green and intelligent technology, Chinese Academy of Sciences, Yin Changcheng, R & D director of Beijing Huada protein R & D Center Co., Ltd., Li Gang, professor and doctoral supervisor of Chongqing University, and Zhao Rongzhi, founder of think tank salon, respectively gave excellent thematic reports.